APTAIT GMBH

Their core work

AptaIT is a German SME whose name signals its core positioning: aptamer science combined with IT and bioinformatics development. In the APERIM project, they contributed to building a computational platform for analyzing cancer immunotherapy data to support personalized treatment decisions. In the MetaRNA project, they participated as a third party in research on RNA-based technologies for detecting metabolites at the single-cell level. Their dual foothold in molecular RNA/aptamer biology and software tooling makes them a bridge partner between laboratory research teams and clinical data infrastructure projects.

What they specialise in

How they've shifted over time

Both of AptaIT's H2020 projects began in 2015, which makes it impossible to observe any meaningful shift in focus across distinct time periods — the organization's visible EU-funded activity is effectively a single snapshot. In that window, they operated across two related but distinct domains: computational bioinformatics for clinical oncology (APERIM) and RNA/aptamer-based molecular sensing (MetaRNA). No keyword data is available to detect finer-grained changes within this period, and no subsequent H2020 projects appear in the record.

With both projects starting in 2015 and no subsequent H2020 activity on record, it is unclear whether AptaIT remains active in EU-funded research — any potential collaborator should verify the organization's current status before engaging.

How they like to work

AptaIT has never coordinated an H2020 project, taking on participant or third-party roles in both cases. Despite being a small SME, they engaged with 23 unique consortium partners across 9 countries through just two projects, indicating comfort in large, internationally distributed consortia. This pattern suggests an organization that brings focused technical expertise to projects led by academic institutions or larger partners, rather than driving coordination themselves.

AptaIT has connected with 23 unique partners across 9 countries through only two projects, which implies they typically work within large multi-partner consortia rather than narrow bilateral arrangements. No dominant geographic cluster is identifiable from available data, though their base in Germany and European-scale partnerships suggest a broadly European reach.

What sets them apart

AptaIT occupies a narrow but genuinely differentiated niche: a private SME that combines aptamer and RNA molecular biology with bioinformatics software development. This dual competency — domain knowledge in molecular sensing alongside IT platform-building — is uncommon among small companies and makes them a useful link between wet-lab research consortia and clinical data infrastructure projects. That said, their EU project record is thin and dated, so any assessment of current capabilities should be confirmed directly with the organization.

Highlights from their portfolio

• APERIM
  Their only directly funded H2020 project (EUR 307,125), tackling a high-impact clinical application: a bioinformatics platform designed to guide personalized cancer immunotherapy decisions.
• MetaRNA
  Participation in an MSCA-ITN-ETN training network demonstrates a connection to next-generation researcher training in RNA sensor technologies, extending their reach into academic talent pipelines.